低分子医薬品原薬の世界市場レポート 2025年

低分子医薬品原薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.0％で2,852億3,000万米ドルに成長します。予測期間の成長は、精密医療、特殊治療、持続可能性への取り組み、遠隔医療の採用、AIの統合に起因すると考えられます。予測期間における主な動向には、アウトソーシング動向、標的治療、製薬におけるデジタル化、仮想臨床試験、高度分析などがあります。

疾病の蔓延拡大は、低分子医薬品原薬（API）市場の拡大を促進する重要な要因です。疾患とは、患者の身体に影響を及ぼす特定の異常な状態、構造や機能の障害と定義されます。医薬品有効成分（API）は、様々な健康状態を治療するために望ましい効果をもたらす医薬品の必須成分です。例えば、2023年3月、米国を拠点とする専門組織である米国臨床腫瘍学会（ASCO）は、米国では年間12,000人以上が神経内分泌腫瘍と診断され、2023年には約171,000人がこの診断を受けながら生活していると報告しました。さらに、心血管疾患は世界中で1,790万人の死亡につながっています。その結果、疾患の有病率の上昇は引き続き低分子API市場の主要な促進要因となっています。

個別化医療の採用の増加は、低分子API市場の成長をさらに促進すると予想されます。個別化医療（精密医療）とは、患者の遺伝子、環境、ライフスタイルの個人差を考慮した先進的な治療アプローチです。低分子は医薬品に配合されることで、患者固有の遺伝子プロファイルやバイオマーカーに対応するように設計されたオーダーメイドの治療を可能にし、より効果的で個別化された治療につながります。例えば、米国を拠点とする専門組織である個別化医療連合（Personalized Medicine Coalition）は、2022年にFDA医薬品評価研究センター（CDER）が37の新規分子生物学的製剤（NME）を承認したと報告しています。この35の治療用NMEのうち、約34％にあたる12医薬品が、個別化医療連合（PMC）によって個別化医療に分類されました。その結果、個別化医療の採用が低分子API市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界低分子医薬品原薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の低分子医薬品原薬市場：成長率分析
• 世界の低分子医薬品原薬市場の実績：規模と成長, 2019-2024
• 世界の低分子医薬品原薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界低分子医薬品原薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の低分子医薬品原薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 合成
• 化学薬品
• 生物学的
• 世界の低分子医薬品原薬市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 自己免疫疾患
• 腫瘍学
• 代謝性疾患
• 眼科
• 心血管疾患
• 感染症
• 神経学
• 呼吸器疾患
• 皮膚科
• 泌尿器科
• 世界の低分子医薬品原薬市場製造方法別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 社内
• 契約
• 世界の低分子医薬品原薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 臨床
• 商業用
• 世界の低分子医薬品原薬市場、合成のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 低分子医薬品
• ジェネリック医薬品
• 世界の低分子医薬品原薬市場、化学品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 有機化合物
• 無機化合物
• 世界の低分子医薬品原薬市場、生物のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 天然製品
• 半合成化合物

第7章 地域別・国別分析

• 世界の低分子医薬品原薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の低分子医薬品原薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 低分子医薬品原薬市場：競合情勢
• 低分子医薬品原薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • BASF SE Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Limited Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Allergan plc
• Bayer AG
• Novartis AG
• Sanofi SA
• Bristol Myers Squibb Company
• AstraZeneca plc
• Glaxo Smith Kline plc
• China Resources Pharmaceutical Group Limited
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Gilead Sciences Inc.
• Boehringer Ingelheim International GmbH
• Merck KGaA
• Viatris Inc.
• Teva Pharmaceutical Industries Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 低分子医薬品原薬市場2029：新たな機会を提供する国
• 低分子医薬品原薬市場2029：新たな機会を提供するセグメント
• 低分子医薬品原薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

A small-molecule active pharmaceutical ingredient (API) is a substance or mixture with a low molecular weight intended for use as the active ingredient in drug or medicinal product manufacturing.

The primary types of small molecule active pharmaceutical ingredient markets are synthetic, chemical, and biological. Synthetics engage in the manufacturing of pharmaceutical drugs, with synthetic chemical APIs, also known as small molecules, constituting a significant portion of the pharmaceutical market. Various therapeutic types, including autoimmune diseases, oncology, metabolic diseases, ophthalmology, cardiovascular diseases, infectious diseases, neurology, respiratory disorders, dermatology, and urology, are addressed. Manufacturing methods involve in-house and contract methods, with applications spanning clinical and commercial domains.

The small molecule active pharmaceutical ingredient market research report is one of a series of new reports from The Business Research Company that provides small molecule active pharmaceutical ingredient market statistics, including small molecule active pharmaceutical ingredient industry global market size, regional shares, competitors with a small molecule active pharmaceutical ingredient market share, detailed small molecule active pharmaceutical ingredient market segments, market trends and opportunities, and any further data you may need to thrive in the small molecule active pharmaceutical ingredient industry. This small molecule active pharmaceutical ingredient market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The small molecule active pharmaceutical ingredient market size has grown strongly in recent years. It will grow from $194.18 billion in 2024 to $209.81 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to regulatory approvals, patent expirations, disease prevalence, pricing pressures, clinical trial outcomes.

The small molecule active pharmaceutical ingredient market size is expected to see strong growth in the next few years. It will grow to $285.23 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to precision medicine, specialty therapeutics, sustainability initiatives, telehealth adoption, integration of AI. Major trends in the forecast period include outsourcing trends, targeted therapies, digitalization in pharma, virtual clinical trials, advanced analytics.

The growing prevalence of diseases is a significant factor driving the expansion of the small molecule active pharmaceutical ingredient (API) market. A disease is defined as a specific abnormal condition, a disruption of structure or function, affecting a patient's body. Active pharmaceutical ingredients (APIs) are the essential components in pharmaceutical drugs that produce the desired effect to treat various health conditions. For example, in March 2023, the American Society of Clinical Oncology (ASCO), a U.S.-based professional organization, reported that over 12,000 individuals in the U.S. were diagnosed with neuroendocrine tumors annually, with around 171,000 people living with this diagnosis in 2023. Additionally, cardiovascular diseases have led to 17.9 million deaths worldwide. As a result, the rising prevalence of diseases continues to be a primary driver of the small molecule API market.

The increasing adoption of personalized medicine is anticipated to further drive the growth of the small molecule API market. Personalized medicine, or precision medicine, is an advanced approach to medical treatment that considers individual variations in patients' genes, environments, and lifestyles. Small molecules, when formulated into pharmaceuticals, enable the creation of tailored treatments designed to address patients' unique genetic profiles and biomarkers, leading to more effective and individualized therapies. For instance, in 2022, the Personalized Medicine Coalition, a U.S.-based professional organization, reported that the FDA's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs) in 2022. Of these 35 therapeutic NMEs, approximately 34%-or 12 drugs-were classified as personalized medicines by the Personalized Medicine Coalition (PMC). Consequently, the adoption of personalized medicine is driving the growth of the small molecule API market.

Strategic partnerships and collaborations are a key trend in the small molecule active pharmaceutical ingredient market, with major players reinforcing their positions through such alliances. In May 2022, NovAliX, Alysophil, De Dietrich Process Systems, and Bruker collaborated to jointly develop a new approach to active pharmaceutical ingredient (API) production. The partnership aims to offer complete, standalone, and location-independent API manufacturing solutions to pharmaceutical companies and contract manufacturing organizations (CMOs).

The key players in the small molecule API market are leveraging new technologies, such as microparticle technologies, to gain a competitive edge. Evonik Industries AG, a Germany-based specialty chemical company, introduced EUDRATEC SoluFlow in March 2022. This technology significantly enhances the solubility of active pharmaceutical ingredients in oral drug products, addressing challenges related to drug solubility. EUDRATEC SoluFlow transforms poorly soluble drugs into free-flowing powders of amorphous solid dispersions, simplifying manufacturing processes and improving pharmacokinetic performance.

In November 2022, Pharmaron Beijing, a China-based life science contract research organization, acquired the API Manufacturing Facility from Recipharm for an undisclosed amount. Through this acquisition, Pharmaron aims to strengthen its integrated chemistry and manufacturing capabilities to meet the increasing demand for small molecule drug R&D and manufacturing services. Active Pharmaceutical Ingredients (API) Manufacturing is a U.S.-based company specializing in the production of small molecule active pharmaceutical ingredients.

Major companies operating in the small molecule active pharmaceutical ingredient market include Pfizer Inc., BASF SE, Roche Holding AG, F. Hoffmann-La Roche Limited, AbbVie Inc., Allergan plc, Bayer AG, Novartis AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Glaxo Smith Kline plc, China Resources Pharmaceutical Group Limited, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Viatris Inc., Teva Pharmaceutical Industries Limited, Johnson Matthey plc, Astellas Pharma Inc., Albemarle Corporation, Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Dr Reddy's Laboratories Limited, Siegfried Holding AG, Albany Molecular Research Inc., Cipla Inc., Cambrex Corporation, Daiichi Sankyo Company Ltd., Eisai Co Ltd., Otsuka Holdings Co Ltd.

North America was the largest region in the small molecule active pharmaceutical ingredient market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the small molecule active pharmaceutical ingredient market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the small molecule active pharmaceutical ingredient market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The small molecule active pharmaceutical ingredient market consists of sales of standard API, HPAPI (high potency active pharmaceutical ingredients), branded synthetic API, generic synthetic API, and semi-synthetic API. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Small Molecule Active Pharmaceutical Ingredient Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on small molecule active pharmaceutical ingredient market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for small molecule active pharmaceutical ingredient ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The small molecule active pharmaceutical ingredient market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Synthetic; Chemical; Biological
• 2) By Therapeutic Type: Autoimmune Diseases; Oncology; Metabolic Diseases; Ophthalmology; Cardiovascular Diseases; Infectious Diseases; Neurology; Respiratory Disorders; Dermatology; Urology
• 3) By Manufacturing Method: In-House; Contract
• 4) By Application: Clinical; Commercial
• Subsegments:
• 1) By Synthetic: Small Molecule Drugs; Generic Drugs
• 2) By Chemical: Organic Compounds; Inorganic Compounds
• 3) By Biological: Natural Products; Semi-Synthetic Compounds
• Companies Mentioned: Pfizer Inc.; BASF SE; Roche Holding AG; F. Hoffmann-La Roche Limited; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Small Molecule Active Pharmaceutical Ingredient Market Characteristics

3. Small Molecule Active Pharmaceutical Ingredient Market Trends And Strategies

4. Small Molecule Active Pharmaceutical Ingredient Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Small Molecule Active Pharmaceutical Ingredient Growth Analysis And Strategic Analysis Framework

• 5.1. Global Small Molecule Active Pharmaceutical Ingredient PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Small Molecule Active Pharmaceutical Ingredient Market Growth Rate Analysis
• 5.4. Global Small Molecule Active Pharmaceutical Ingredient Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Small Molecule Active Pharmaceutical Ingredient Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Small Molecule Active Pharmaceutical Ingredient Total Addressable Market (TAM)

6. Small Molecule Active Pharmaceutical Ingredient Market Segmentation

• 6.1. Global Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Synthetic
• Chemical
• Biological
• 6.2. Global Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Therapeutic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Autoimmune Diseases
• Oncology
• Metabolic Diseases
• Ophthalmology
• Cardiovascular Diseases
• Infectious Diseases
• Neurology
• Respiratory Disorders
• Dermatology
• Urology
• 6.3. Global Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Manufacturing Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• In-House
• Contract
• 6.4. Global Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinical
• Commercial
• 6.5. Global Small Molecule Active Pharmaceutical Ingredient Market, Sub-Segmentation Of Synthetic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small Molecule Drugs
• Generic Drugs
• 6.6. Global Small Molecule Active Pharmaceutical Ingredient Market, Sub-Segmentation Of Chemical, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Organic Compounds
• Inorganic Compounds
• 6.7. Global Small Molecule Active Pharmaceutical Ingredient Market, Sub-Segmentation Of Biological, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Natural Products
• Semi-Synthetic Compounds

7. Small Molecule Active Pharmaceutical Ingredient Market Regional And Country Analysis

• 7.1. Global Small Molecule Active Pharmaceutical Ingredient Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Small Molecule Active Pharmaceutical Ingredient Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Small Molecule Active Pharmaceutical Ingredient Market

• 8.1. Asia-Pacific Small Molecule Active Pharmaceutical Ingredient Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Therapeutic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Manufacturing Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Small Molecule Active Pharmaceutical Ingredient Market

• 9.1. China Small Molecule Active Pharmaceutical Ingredient Market Overview
• 9.2. China Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Therapeutic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Manufacturing Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Small Molecule Active Pharmaceutical Ingredient Market

• 10.1. India Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Therapeutic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Manufacturing Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Small Molecule Active Pharmaceutical Ingredient Market

• 11.1. Japan Small Molecule Active Pharmaceutical Ingredient Market Overview
• 11.2. Japan Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Therapeutic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Manufacturing Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Small Molecule Active Pharmaceutical Ingredient Market

• 12.1. Australia Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Therapeutic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Manufacturing Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Small Molecule Active Pharmaceutical Ingredient Market

• 13.1. Indonesia Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Therapeutic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Manufacturing Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Small Molecule Active Pharmaceutical Ingredient Market

• 14.1. South Korea Small Molecule Active Pharmaceutical Ingredient Market Overview
• 14.2. South Korea Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Therapeutic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Manufacturing Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Small Molecule Active Pharmaceutical Ingredient Market

• 15.1. Western Europe Small Molecule Active Pharmaceutical Ingredient Market Overview
• 15.2. Western Europe Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Therapeutic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Manufacturing Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Small Molecule Active Pharmaceutical Ingredient Market

• 16.1. UK Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Therapeutic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Manufacturing Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Small Molecule Active Pharmaceutical Ingredient Market

• 17.1. Germany Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Therapeutic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Manufacturing Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Small Molecule Active Pharmaceutical Ingredient Market

• 18.1. France Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Therapeutic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Manufacturing Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Small Molecule Active Pharmaceutical Ingredient Market

• 19.1. Italy Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Therapeutic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Manufacturing Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Small Molecule Active Pharmaceutical Ingredient Market

• 20.1. Spain Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Therapeutic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Manufacturing Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Small Molecule Active Pharmaceutical Ingredient Market

• 21.1. Eastern Europe Small Molecule Active Pharmaceutical Ingredient Market Overview
• 21.2. Eastern Europe Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Therapeutic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Manufacturing Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Small Molecule Active Pharmaceutical Ingredient Market

• 22.1. Russia Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Therapeutic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Manufacturing Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Small Molecule Active Pharmaceutical Ingredient Market

• 23.1. North America Small Molecule Active Pharmaceutical Ingredient Market Overview
• 23.2. North America Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Therapeutic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Manufacturing Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Small Molecule Active Pharmaceutical Ingredient Market

• 24.1. USA Small Molecule Active Pharmaceutical Ingredient Market Overview
• 24.2. USA Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Therapeutic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Manufacturing Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Small Molecule Active Pharmaceutical Ingredient Market

• 25.1. Canada Small Molecule Active Pharmaceutical Ingredient Market Overview
• 25.2. Canada Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Therapeutic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Manufacturing Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Small Molecule Active Pharmaceutical Ingredient Market

• 26.1. South America Small Molecule Active Pharmaceutical Ingredient Market Overview
• 26.2. South America Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Therapeutic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Manufacturing Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Small Molecule Active Pharmaceutical Ingredient Market

• 27.1. Brazil Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Therapeutic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Manufacturing Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Small Molecule Active Pharmaceutical Ingredient Market

• 28.1. Middle East Small Molecule Active Pharmaceutical Ingredient Market Overview
• 28.2. Middle East Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Therapeutic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Manufacturing Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Small Molecule Active Pharmaceutical Ingredient Market

• 29.1. Africa Small Molecule Active Pharmaceutical Ingredient Market Overview
• 29.2. Africa Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Therapeutic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Small Molecule Active Pharmaceutical Ingredient Market, Segmentation By Manufacturing Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Small Molecule Active Pharmaceutical Ingredient Market Competitive Landscape And Company Profiles

• 30.1. Small Molecule Active Pharmaceutical Ingredient Market Competitive Landscape
• 30.2. Small Molecule Active Pharmaceutical Ingredient Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. BASF SE Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. F. Hoffmann-La Roche Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Small Molecule Active Pharmaceutical Ingredient Market Other Major And Innovative Companies

• 31.1. Allergan plc
• 31.2. Bayer AG
• 31.3. Novartis AG
• 31.4. Sanofi SA
• 31.5. Bristol Myers Squibb Company
• 31.6. AstraZeneca plc
• 31.7. Glaxo Smith Kline plc
• 31.8. China Resources Pharmaceutical Group Limited
• 31.9. Takeda Pharmaceutical Company Limited
• 31.10. Eli Lilly and Company
• 31.11. Gilead Sciences Inc.
• 31.12. Boehringer Ingelheim International GmbH
• 31.13. Merck KGaA
• 31.14. Viatris Inc.
• 31.15. Teva Pharmaceutical Industries Limited

32. Global Small Molecule Active Pharmaceutical Ingredient Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Small Molecule Active Pharmaceutical Ingredient Market

34. Recent Developments In The Small Molecule Active Pharmaceutical Ingredient Market

35. Small Molecule Active Pharmaceutical Ingredient Market High Potential Countries, Segments and Strategies

• 35.1 Small Molecule Active Pharmaceutical Ingredient Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Small Molecule Active Pharmaceutical Ingredient Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Small Molecule Active Pharmaceutical Ingredient Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer